The National Institutes of Health said Thursday that an antiviral often used to treat mpox did not resolve patients’ symptoms faster than placebo in a randomized trial.
The results are notable because the drug, tecovirimat, has rarely been studied clinically for mpox, despite its wide use during the 2022 and 2023 outbreaks in the U.S. and Europe.
... The reason COVID-19 cases are increasing this summer is likely because people who haven’t been recently vaccinated or infected have fewer antibodies at the ready to fight off the first sign of the virus and are more likely to experience its symptoms, including fever, chills, sore throat, cough, congestion, body aches, gastrointestinal issues, and fatigue.
... the study found that individuals with a favorable lifestyle had a lower risk of hospitalization, lower incidence of long-term or on-going health issues affecting multiple parts of the body, and reduced risk of post-COVID death, compared to those with an unfavorable lifestyle.
Recent Comments